Optimizing Urology Denial Appeal Automation

Klivira's platform delivers robust urology denial appeal automation, transforming a historically manual, resource-intensive process into an efficient, data-driven workflow.

For urology practices, hospitals, and health systems, managing prior authorization denials for high-cost drugs and complex procedures presents a significant revenue cycle challenge. Klivira addresses this by automating critical steps in the appeal process, from denial classification to submission, ensuring timely and compliant resolutions.

The Impact of Denials in Urology

Urology practices frequently encounter denials for high-volume categories such as prostate cancer therapeutics (e.g., androgen deprivation therapies, oral AR inhibitors, PSMA-targeted radiopharmaceuticals), advanced BPH treatments (e.g., UroLift, Rezum, Aquablation), OAB medications (e.g., mirabegron, onabotulinumtoxinA), and advanced imaging (e.g., multiparametric prostate MRI, PSMA PET). Common denial reasons include step therapy requirements for ED/OAB treatments, medical-necessity gaps for advanced prostate cancer drugs, NCD/LCD constraints for PSMA imaging, and insufficient conservative therapy documentation for BPH/OAB. Each denial triggers costly rework and delays patient care.

Common Urology PA Triggers and Denial Hotspots

Prostate cancer treatments: Lupron, Xtandi, Zytiga, Pluvicto, PSMA PET imaging (Gallium-68 PSMA, Pylarify/F-18-DCFPyL).
BPH treatments: UroLift, Rezum, Aquablation, TURP, prostatectomy.
Overactive bladder treatments: Myrbetriq, Botox injections, sacral neuromodulation (InterStim).
Robotic urologic surgery: prostatectomy, partial/radical nephrectomy, cystectomy.
Imaging: multiparametric prostate MRI, CT urogram, PSMA imaging for staging.

Automated Appeal Letter Generation for Urology-Specific Denials

Klivira's platform automates the drafting of appeal letters by leveraging normalized CARC/RARC taxonomy to classify denials and match them to payer-specific templates. For clinical-necessity appeals common in urology—such as those for advanced prostate cancer drugs or complex surgical procedures—Klivira drafts a clinician-reviewable letter, incorporating relevant clinical evidence and literature citations, which the urologist can approve or edit before submission.

Intelligent Clinical Evidence Extraction for Urology Appeals

Automated FHIR-based re-discovery of documentation from the EMR, including notes added since initial PA submission.
Extraction of specific urology-relevant data points: Gleason score, PSA levels, NCCN-compendium-supported indications for oncology drugs.
Identification of IPSS scores, prostate size, and prior medical therapy trial durations for BPH treatments.
Documentation of biochemical recurrence or initial staging indications for PSMA imaging, aligning with NCCN guidelines.
Proof of failed conservative therapy for OAB and neuromodulation, including trial-phase results for InterStim.

Streamlined Payer Engagement and Timely Filing

Klivira navigates the complex landscape of payer appeal channels, submitting appeals via payer portals, fax, or PAS-conformant resubmission where applicable. The platform's payer-policy library encodes per-payer appeal-pathway specifications, ensuring the correct appeal level is invoked and timely-filing windows are strictly enforced. Automated tracking of appeal status, outcomes, and next-step deadlines prevents lost-to-follow-up appeals, a critical component for high-urgency prostate cancer cases.

Driving Continuous Improvement in Urology Prior Authorization

Beyond individual appeal resolution, Klivira captures appeal outcomes and feeds success patterns by denial reason and payer back into upstream prior authorization submission processes. This data-driven feedback loop helps urology practices refine their initial PA submissions, proactively address common denial triggers, and align documentation with AUA Clinical Practice Guidelines and NCCN for urologic oncology, ultimately reducing future denial rates.

Frequently asked questions

How does Klivira handle denials for prostate cancer medications?

Klivira's platform is designed to extract key clinical data like Gleason score, PSA, and NCCN-compendium-supported indications from your EMR. This evidence is then automatically incorporated into appeal letters, addressing medical-necessity gaps often cited in denials for advanced prostate cancer therapeutics.

Can Klivira integrate with our EMR to pull urology-specific clinical notes for appeals?

Yes, Klivira utilizes FHIR-based re-discovery to pull additional clinical documentation directly from your EMR. This includes new imaging reports, updated problem lists, and specific notes detailing conservative therapy trials or symptom scores (e.g., IPSS) relevant to urology appeals.

What types of urology denials does Klivira's automation address?

Klivira addresses a wide range of urology denials, including those related to step therapy for ED/OAB drugs, medical necessity for high-cost prostate cancer treatments, NCD/LCD constraints for PSMA imaging, and insufficient documentation of conservative therapy for BPH and OAB treatments.

How does Klivira ensure appeal letters meet payer requirements for urology procedures?

Klivira's payer-policy library contains per-payer appeal-pathway specifications, including required documentation and template variations. This ensures that appeal letters for procedures like UroLift, Aquablation, or robotic surgeries are composed to meet specific payer criteria, enhancing the likelihood of approval.

Does Klivira help track the status of urology appeals?

Yes, Klivira provides automated status tracking for all submitted appeals, including timely-filing window enforcement and escalation rules. This ensures that urology appeals for time-sensitive treatments are not lost to follow-up and progress efficiently through the payer's review process.